Oral Methylthioadenosine Administration Attenuates Fibrosis and Chronic Liver Disease Progression in Mdr2-/- Mice

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Latasa, M Ujue ^a   Gil Puig, Carmen ^a,b   Fernández Barrena, Maite G ^a,c   Rodríguez Ortigosa, Carlos M ^a,c   Banales, Jesús M ^a,c   Urtasun, Raquel ^a   Goñi, Saioa ^a   Méndez, Miriam ^a   Arcelus, Sara ^c   Juanarena, Nerea ^a   Recio, Juan A ^d   Lotersztajn, Sophie ^e,f   Prieto, Jesús ^a,c   Berasain, Carmen ^a   Corrales, Fernando J ^a   Lecanda, Jon ^a,b   Ávila, Matías A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Digna Biotech   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e INSERM U955   (France)

^f UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; CYCLIN D1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TENASCIN; TRANSCRIPTION FACTOR JUND; TRANSFORMING GROWTH FACTOR BETA2; 2 METHYLTHIOADENOSINE; 2-METHYLTHIOADENOSINE; ADENOSINE; CYTOKINE; DRUG DERIVATIVE; GLYCOPROTEIN P; JUND PROTEIN, MOUSE; NUCLEOSIDE; P GLYCOPROTEIN 2; P-GLYCOPROTEIN 2; PROTEIN C JUN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION; HEPATOMEGALY; IMMUNOREACTIVITY; IN VIVO STUDY; LIVER FIBROSIS; LIVER INJURY; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; FIBROBLAST; FIBROSIS; GENETICS; INFLAMMATION; LIVER; LIVER DISEASE; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

MUS;

ADENOSINE; ANIMALS; CYCLIN D1; CYTOKINES; DISEASE PROGRESSION; FIBROBLASTS; FIBROSIS; INFLAMMATION; LIVER; LIVER DISEASES; MICE; MICE, TRANSGENIC; P-GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; THIONUCLEOSIDES;

EID: 78650835714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015690     Document Type: Article

References (69)

1. Williams R (2006) Global challenges in liver disease. Hepatology 44: 521-6.
2. Siegel AB, Zhu AX (2009) Metabolic syndrome and hepatocellular carcinoma. Cancer 115: 5651-5661.
3. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115: 209-218.
4. Elsharkawy AM, Mann DA (2007) Nuclear factor-kB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46: 590-597.
5. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A (2005) Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 45: 605-628.
6. Pikarski E, Porat RM, Stein I, Abramovitch R, Amit S, et al. (2004) NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466.
7. Berasain C, Castillo J, PerugorriaMJ, Latasa MU, Prieto J, et al. (2009) Inflammation and liver cancer: new molecular links. Ann NY Acad Sci; 1155: 206-221.
8. Pinzani M, Rombouts K, Colagrande S (2005) Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42(Suppl): S22-S36.
9. Popov Y, Schuppan D (2009) Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 50: 1294-1306.
10. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, et al. (2004) Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127: 261-274.
11. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D (2005) Mdr2 (Abcb4)-/-mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro-and antifibrogenic genes. J Hepatol 43: 1045-1054.
12. Nakken KE, Nygård S, Haaland T, Berge KE, Arnkværn K, et al. (2007) Multiple inflammatory-, tissue remodelling-and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/-) mice harbouring chronic cholangitis. Scand J Gastroenterol 42: 1245-1255.
13. Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, et al. (2008) Inhibition of integrin avb6 on cholangiocytes blocks transforming growth factorb activation and retards biliary fibrosis progression. Gastroenterology 135: 660-670.
14. Katzenellenbogen M, Pappo O, Barash H, Klopstock N, Mizrahi L, et al. (2006) Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res 66: 4001-4010.
15. Avila MA, Garcia-Trevijano ER, Lu SC, Corrales FJ, Mato JM (2004) Methylthioadenosine. Int J Biochem Cell Biol 36: 2125-2130.
16. Hevia H, Varela-Rey M, Corrales FJ, Berasain C, Martínez-Chantar ML, et al. (2004) 59-Methythioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. Hepatology 39: 1088-1098.
17. Moreno B, Hevia H, Santamaria M, Sepulcre J, Muñoz J, et al. (2006) Methylthioadenosine reverses brain autoimmune disease. Ann Neurol 60: 323-334.
18. Iglesias-Ara A, Xia M, Ramani K, Mato JM, Lu SC (2008) S-Adenosylmethionine inhibits lipopolysaccharide-induced gene expression via modulation of histone methylation. Hepatology 47: 1655-1666.
19. Simile MM, Banni S, Angioni E, Carta G, De Miglio MR, et al. (2001) 59-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol 34: 386-394.
20. Pascale RM, Simile MM, De Miglio MR, Feo F (2002) Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 27: 193-198.
21. Berasain C, Hevia H, Fernández-Irigoyen J, Larrea E, Caballería J, et al. (2004) Methylthioadenosine phosphorylase gene expression is impaired in human liver cirrhosis and hepatocarcinoma. Biochim Biophys Acta 1690: 276-284.
22. Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, et al. (2008) The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology 48: 1251-1261.
23. Li LY, Grenard P, Van Nhieu JT, Julien B, Mallat A, et al. (2003) Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 125: 460-469.
24. El-Karef A, Yoshida T, Gabazza EC, Nishioka T, Inada H, et al. (2007) Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol 211: 86-94.
25. Eto I. Molecular cloning and sequence analysis of the promoter region of mouse cyclin D1 gene. Cell Prolif 2000; 33: 167-187.
26. El-Karef A, Kaito M, Tanaka H, Ikeda K, Nishioka T, et al. (2007) Expression of large tenascin-C splice variants by hepatic stellate cells/myofibroblasts in chronic hepatitis C. J Hepatol 46: 664-673.
27. Mann J, Mann DA (2009) Transcriptional regulation of hepatic stellate cells. Adv Drug Delivery Rev 61: 497-512.
28. Tao J, Mallat A, Gallois C, Belmadani S, Méry PF, et al. (1999) Biological effects of C-type natriuretic peptide in human myofibroblastic hepatic stellate cells. J Biol Chem 274: 23761-23769.
29. Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, et al. (2010) Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138: 347-359.
30. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, et al. (2010) Curcumin improves sclerosing cholangitis in Mdr2-/-mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 59: 521-530.
31. Mato JM, Martínez-Chantar ML, Lu SC (2008) Methionine metabolism and liver disease. Annu Rev Nutr 28: 273-293.
32. Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, et al. (2007) Molecular mechanisms of liver carcinogenesis in the Mdr2-knockout mice. Mol Cancer Res 5: 1159-1170.
33. Jacobson KA, Gao Z (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discovery 5: 247-264.
34. Haskó G, Csóka B, Németh ZH, Vizi ES, Pacher P (2009) A2B adenosine receptors in immunity and inflammation. Trends Immunol. 30: 263-270.
35. Munshi R, Clanachan AS, Baer HP (1988) 59-deoxy-59-methylthioadenosine: a nucleoside which differentiates between adenosine receptor types. Biochem Pharmacol 37: 2085-2089.
36. Németh ZH, Leibovich SJ, Deitch EA, Vizi S, Szabó C, et al. (2003) cDNA Microarray analysis reveals a nuclear factor-kB-independent regulation of macrophage function by adenosine. J Pharmacol Exp Ther 306: 1042-1049.
37. Németh ZH, Lutz CS, Csóka B, Deitch EA, Leibovich SJ, et al. (2005) Adenosine augments IL-10 production by macrophages through an A2B recptormediated posttranscriptional mechanism. J Immunol 175: 8260-8270.
38. Kreckler LM, Wan TC, Ge Z, Auchampach JA (2006) Adenosine inhibits tumor necrosis factor-a release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther 317: 172-180.
39. Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Blackburn MR, et al. (2008) Effetc of A2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. J Pharm Exp Ther 324: 694-700.
40. Aherne CM, Kewley EM, Eltzschig HK (2010) The resurgence of A2B adenosine receptor signalling. Biochim Biophys Acta May 27. [Epub ahead of print].
41. Dranoff JA, Wells RG (2010) Portal fibroblasts: underappreciated mediators of biliary fibrosis. Hepatology 51: 1438-1444.
42. Smart DE, Green K, Oakley F, Weitzman JB, Yaniv M, et al. (2006) JunD is a profibrogenic transcription factor regulated by Jun N-terminal kinase-independent phosphorylation. Hepatology 44: 1432-1440.
43. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA (2007) A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130: 77-88.
44. Song M-R, Ghosh A (2004) FGF2-induced chromatin remodelling regulates CNTF-mediated gene expression and astrocyte differentiation. Nat Neurosci 7: 229-235.
45. Gäbele E, Reif S, Tsukada S, Bataller R, Yata Y, et al. (2005) The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol Chem 280: 13374-13382.
46. Yang H, Ramani K, Xia M, Ko KS, Li TWH, et al. (2009) Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology 49: 1982-1991.
47. Ju M, Qiu S, Fan J, Xiao Y, Gao Q, et al. (2009) Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma. Am J Clin Pathol 131: 498-510.
48. Spirli C, Fabris L, Duner E, Fiorotto R, Roskams T, et al. (2003) Cytokinestimulated nitric oxide production inhibits adenylyl cyclase and cAMPdependent secretion in cholangiocytes. Gastroenterology 124: 737-753.
49. Sitkovsky MV (2003) Use of the A2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 65: 493-501.
50. Csóka B, Németh ZH, Rosenberger P, Eltzschig HK, Spolarics Z, et al. (2010) A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 185: 542-550.
51. Ansorena E, Garcia-Trevijano ER, Martinez-Chantar ML, Huang Z, Chen L, et al. (2002) S-Adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology 35: 274-280.
52. Ansorena E, Berasain C, López Zabalza MJ, Avila MA, García-Trevijano ER, et al. (2006) Differential regulation of the JNK/AP-1 pathway by Sadenosylmethionine and methylthioadenosine in primary rat hepatocytes versus HuH7 hepatoma cells. Am J Physiol Gastrointest Liver Physiol 290: G1186-G1193.
53. Marderstein EL, Bucher B, Guo Z, Feng X, Reid K, et al. (2003) Protection of rat hepatocytes from apoptosis by inhibition of c-Jun N-terminal kinase. Surgery 134: 280-284.
54. Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter G, et al. (2005) JNK mediates hepatic ischemia reperfusion injury. J Hepatol 42: 850-859.
55. Gunawan BK, Liu ZX, Hanawa N, Gaarde WA, Kaplowitz N (2006) c-Jun Nterminal kinase plays a major role in murine acetaminophen hepatotocicity. Gastroenterology 131: 165-178.
56. Nieto N, Cederbaum AI, S-Adenosylmethionine blocks collagen I production by preventing transforming growth factor-b induction of the COL1A2 promoter (2005) J Biol Chem 280: 30963-30974.
57. Marra F, DeFranco R, Grappone C,Milani S, Pastacaldi S, et al. (1998) Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152: 423-430.
58. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
59. Schuppan D, Popov Y (2009) Rationale and targets for antifibrotic therapies. Gastroenterol Clin Biol 33: 949-957.
60. Zamara E, Galastri S, Aleffi S, Petrai I, Aragno M, et al. (2007) Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol 46: 230-238.
61. Marra F, Valente AJ, Pinzani M, Abboud HE (1993) Cultured human liver fatstoring cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J Clin Invest 92: 1674-1680.
62. Kruglov EA, Nathanson RA, Nguyen T, Dranoff JA (2006) Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic trasndifferentiation of portal fibroblasts. Am J Physiol Gastrointest Liver Physiol 290: G765-G771.
63. Kawada N, Ikeda K, Seki S, Kuroki T (1999) Expression of cyclins D1, D2 and E correlates with proliferation of rat stellate cells in culture. J Hepatol 30: 1057-1064.
64. Wysoka J, Swigut T, Xiao H, Milne TA, Kwon SY, et al. (2006) A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442: 86-90.
65. Mann J, Chu DCK, Maxwell A, Oakley F, Zhu N, Tsukamoto H, Mann DA. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138: 705-714.
66. Chen H, Xia M, Lin M, Yang H, Kuhlenkamp J, et al. (2007) Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogeninduced growth of human colon cancer cells. Gastroenterology 133: 207-219.
67. Andreu-Perez P, Hernandez-Losa J, Moline T, Gil R, Grueso J, et al. (2010) Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth. BMC Cancer 10: 265.
68. Stramentinoli G, Gennari F. Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle. Stramentinoli patent 4,454,122. Filed: Aug 6, 1982; Issued: Jun 12, 1984.
69. Moratti E. Pharmaceutical compositions containing 5-deoxy-5-methylthioadenosine s-adenosylmethionine and their salts for reducing seborrhoea. Moratti patent 5,753,213. Filed: Mar 13, 1990; Issued: May 19, 1998.